---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000199"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:19:45.447007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurocrine's NBI-1117568 meets Phase 2 primary endpoint; 7.5-point PANSS reduction vs placebo

## Summary
- 20 mg once-daily dose met primary endpoint: placebo-adjusted PANSS reduction of 7.5 points (p=0.011, effect size 0.61) at Week 6.
- Dose also statistically significant on CGI-S, Marder positive and negative symptom scores.
- NBI-’568 well tolerated; no weight gain vs placebo; GI events low; discontinuation rates similar to placebo.
- Company plans to advance NBI-’568 into Phase 3 development in schizophrenia in early 2025.
- Other doses (40 mg, 60 mg QD, 30 mg BID) did not reach statistical significance on primary endpoint.

## SEC filing metadata
- accession: 0000914475-24-000199
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000199/0000914475-24-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000199/nbix-20240828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000199
- JSON: https://secwatch.observer/filing/0000914475-24-000199.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.